References
- Green F, Humphries S. Control of plasma fibrinogen levels. Baillieres Clin Haematol 1989;24:945–59.
- Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000;21:1574–83.
- Acharya SS, Dimichele DM. Rare inherited disorders of fibrinogen. Haemophilia 2008;14:1151–8.
- Mammen EF. Coagulopathies of liver disease. Clin Lab Med 1994;14:769–80.
- Chen HF, Xu LP, Luo ZY, Yu ZQ, Li ZY, Cui QY, et al. Valproic acid-associated low fibrinogen and delayed intracranial hemorrhage: case report and mini literature review. Drug Des Devel Ther 2013;7:767–70.
- Kose G, Arhan E, Unal B, Ozaydin E, Guven A, Sayli TR. Valproate-associated coagulopathies in children during short-term treatment. J Child Neurol 2009;24:1493–8.
- Tokuda K, Kodani N, Ogino T. [Three cases of hypofibrinogenemia induced by chemotherapy with a combination of synthetic ACTH and valproic acid.] No To Hattatsu 1994;26:50–6 (in Japanese).
- Yokose N, Ogata K, Nakamura K, Kamikubo K, Tamura H, An E, et al. Hypofibrinogenemia induced by prednisolone therapy in a patient with chronic lymphocytic leukemia complicated with autoimmune hemolytic anemia. Am J Hematol 1997;55:166–7.
- Fujieda H, Hojo H, Ohyashiki JH, Ohyashiki K, Toyama K, Baba Y. [Transient hypofibrinogenemia induced by prednisolone in a case of acute lymphoblastic leukemia.] Rinsho Ketsueki 1989;30:1037–41 (in Japanese).
- Beinart G, Damon L. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol 2004; 77:331–5.
- Yin Z, Xu J, Li Y, Xia J, Luo D. Transient hypofibrinogenemia due to allopurinol. Drug Des Devel Ther 2014;8:1231–3.
- Pieringer H, Schmekal B, Biesenbach G, Pohanka E. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline. Ann Hematol 2010;89:1063–4.
- Rossitto G, Piano S, Rosi S, Simioni P, Angeli P. Life- threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis. Eur J Gastroenterol Hepatol 2014;26:681–4.
- Greer ND. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 2006; 19:155–61.
- Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000; 20(Pt 2):219S–23S; discussion 24S–28S.
- Administration USFDA. FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. US Department of Health and Human Services; 2010.
- Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/pharmacodynamic profile for tigecycline – a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005;52:165–71.
- Routsi C, Kokkoris S, Douka E, Ekonomidou F, Karaiskos I, Giamarellou H. High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. Int J Antimicrob Agents 2015;45:90–3.
- Shirakawa H, Komai M, Kimura S. Antibiotic-induced vitamin K deficiency and the role of the presence of intestinal flora. Int J Vitam Nutr Res 1990;60:245–51.
- Wang HJ, Deng J, Wang JY, Zhang PJ, Xin Z, Xiao K, et al. Serum miR-122 levels are related to coagulation disorders in sepsis patients. Clin Chem Lab Med 2014;52:927–33.
- Fish RJ, Neerman-Arbez M. Fibrinogen gene regulation. Thromb Haemost 2012;108:419–26.